Selected Key Figures*

The fiscal year of HELLA ends on May 31.

* Please observe the remarks on the Yearly Figures.

Yearly figures

Key figure in € million	2020/2021	2019/2020	2018/2019
Sales [currency- and portfolio adjusted]	6,380 [6.505]	5,829 [5,739]	6,990 [6,770]
Change compared to previous period	9% [13%]	-17% [-16%]	-1% [5%]
EBIT [adjusted]	454 [510]	-343 [227]	808 [572]
Change compared to previous period	232% [125%]	-142% [-60%]	41% [5%]
EBITDA [adjusted]	894 [917]	576 [661]	1,191 [948]
Change compared to previous period	55% [39%]	52% [-30%]	17% [-4%]
Earnings for the period	360	-432	630
Change compared to previous period	183%	-168%	62%
Earnings per share (in €)	3.22	-3.88	5.67
Change compared to previous period	183%	-168%	62%
R&D expenses	603	620	611
Change compared to previous period	-3%	2%	7%
Free Cashflow from operating activities [adjusted]	74 [217]	205 [222]	253 [243]
Change compared to previous period	-64% [-2%]	-19% [-9%]	16% [9%]
Capital expediture	630	431	551
Change compared to previous period	46%	-22%	28%

EBIT margin [adjusted]	7.1% [8.0%]	-5.9% [4.0%]	11.6% [8.4%]
EBITDA margin [adjusted]	14.0% [14.4%]	9.9% [11.5%]	17.0% [14.0%]
R&D expenses in relation to sales	9.5%	10.8%	9.0%
Capital expediture in relation to sales	9.9%	7.5%	7.9%

	May 31, 2021	May 31, 2020	May 31, 2019
Net financial liquidity / debt	103	-140	66
Equity ratio	40.6%	37.0%	46.3%
Return on equity (last 12 months)	13.7%	-20.5%	25.4%
Number of employees (headcount; not in € million)	36.500	36,311	38,845

For further information, please refer to the nine-month financial statement for the fiscal year 2021/2022.

Key Figures in € million	3rd quarter FY 2021/2022	3rd quarter FY 2020/2021	Change to prior year
Sales [currency and portfolio-adjusted]	1,616 [1,583]	1,545 [1,545]	4.6% [2.4%]
EBIT [adjusted]	76 [82]	219 [104]	-65.3% [-21.0%]
EBITDA [adjuste0d]	181 [188]	317 [203]	-42.9% [-7.5%]
Earnings for the period	50	170	-70.6%
Earnings per share (in €)	0.44	1.52	-71.1%
Free cashflow from operating activities [adjusted]	-43 [-25]	102 [113]	--
R&D expenses	169	149	14.0%
Capital expenditure	114	110	3.8%

EBIT margin [adjusted]	4.7% [5.1%]	14.1% [6.7%]	-9.5pp [-1.7pp]
EBITDA margin [adjusted]	11.2% [11.6%]	20.5% [13.1%]	-9.3pp [-1.5pp]
R&D expenses in relation to sales	10.5%	9.6%	+0.9pp
Capital expenditure in relation to sales	7.1%	7.2%	-0.1pp

Key Figures in € million	Nine Months FY 2021/2022	Nine Months FY 2020/2021	Change to prior year
Sales [currency and portfolio- adjusted]	4,653 [4,602]	4,646 [4,646]	0.2% [ -0.9%]
EBIT [adjusted]	225 [238]	312 [373]	-28.0% [ -36.2%]
EBITDA [adjusted]	529 [541]	594 [655]	-10.9% [ -17.3%]
Earnings for the period	154	236	-35.0%
Earnings per share (in €)	1.37	2.12	-35.5%
Free Cashflow from operating activities [adjusted]	-269 [-228]	69 [97]	--
R&D expenses	507	445	13.9%
Capital expenditure	401	371	8.0%

EBIT margin [adjusted]	4.8% [5.1%]	6.7% [8.0%]	-1.9pp [-2.9pp]
EBITDA margin [adjusted]	11.4% [11.6%]	12.8% [14.1%]	-1.4pp [-2.5pp]
R&D expenses in relation to sales	10.9%	9.6%	+1.3pp
Capital expenditure in relation to sales	8.6%	8.0%	+0.6pp

	28 Feb 22	31 May 21
Net financial debt /net financial liquidity (in € million)	-352	103	--
Equity ratio	42.2%	40.6%	+1.6pp
Return on equity (last 12 months)	10.6%	14.6%	-4.1p
Number of employees (headcount)	36,092	36,500	-1.1%